News Future uncertain for Innate and BMS' troubled lirilumab Doubts over future of cancer immunotherapy
News NICE okays CDF funding for BMS' Opdivo in head and neck canc... Cancer Drugs Fund will reimburse Opdivo for 2 years
News BMS' Opdivo approved in head and neck cancer BMS hopes survival data will give advantage over rival.
News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
Digital On the future of AI in life sciences, with women at the helm Dive into a conversation on women in AI, with: Kate Eversole, Pharma Brands; Celine Parmentier, Real Chemistry; and Emma Slade, Tangram Therapeutics.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
